Home > Teams > Infectious Diseases with special emphasis on Co-Morbidities > Circulating Nucleic Acid Biomarker Core Group
The early diagnosis of the onset of chronic and infectious diseases is essential for their successful treatment. We are working on the development of non-invasive tests for the early detection of diseases such as cancers, sepsis or viral infections using molecular markers, which are present in the blood stream of patients. Circulating Nucleic Acids (CNA), which are packaged into exosomes can be used as a target for the development of qPCR assays, which can be performed routinely at the clinics or in blood laboratories. It is our goal to identify molecular markers, which are informative of the presence of early disease stages and work with industrial partners to create tests, which can either be used during an annual check up or when a patient is suspected of developing the condition.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 739593. HCEMM supported by EU Programme: H2020-EU.4.a. – Teaming of excellent research institutions and low performing RDI regions. Project starting date was 1 April 2017.